Tibet Rhodiola Pharmaceutical Holding Co (600211) — Cash Flow-to-Debt Ratio
Tibet Rhodiola Pharmaceutical Holding Co (600211) has a Cash Flow-to-Debt Ratio of 0.14x as of December 2025, meaning its operating cash flow of CN¥297.86 Million could theoretically repay 0% of its total liabilities (CN¥2.10 Billion) in one year. See 600211 financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Tibet Rhodiola Pharmaceutical Holding Co Cash Flow-to-Debt Ratio (1999–2025)
Historical debt coverage capacity for Tibet Rhodiola Pharmaceutical Holding Co across 27 annual periods. For the full cash flow conversion analysis, see how efficiently does Tibet Rhodiola Pharmaceutical Holding Co generate cash.
Annual Cash Flow-to-Debt Ratio for Tibet Rhodiola Pharmaceutical Holding Co (1999–2025)
Year-by-year debt coverage analysis for Tibet Rhodiola Pharmaceutical Holding Co. Check Tibet Rhodiola Pharmaceutical Holding Co cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | 0.49x | CN¥1.03 Billion | CN¥2.10 Billion | ▼ -60.9% |
| 2024 | 1.25x | CN¥994.79 Million | CN¥795.23 Million | ▲ +40.3% |
| 2023 | 0.89x | CN¥1.08 Billion | CN¥1.21 Billion | ▲ +13.8% |
| 2022 | 0.78x | CN¥837.38 Million | CN¥1.07 Billion | ▲ +147.5% |
| 2021 | 0.32x | CN¥366.53 Million | CN¥1.16 Billion | ▼ -73.7% |
| 2020 | 1.20x | CN¥428.17 Million | CN¥355.91 Million | ▼ -21.3% |
| 2019 | 1.53x | CN¥489.59 Million | CN¥320.44 Million | ▲ +45.2% |
| 2018 | 1.05x | CN¥289.22 Million | CN¥274.89 Million | ▲ +227.4% |
| 2017 | 0.32x | CN¥91.46 Million | CN¥284.64 Million | ▲ +109.6% |
| 2016 | 0.15x | CN¥250.21 Million | CN¥1.63 Billion | ▼ -74.8% |
| 2015 | 0.61x | CN¥133.93 Million | CN¥220.43 Million | ▲ +371.7% |
| 2014 | -0.22x | CN¥-141.40 Million | CN¥632.26 Million | ▼ -159.1% |
| 2013 | 0.38x | CN¥279.22 Million | CN¥738.26 Million | ▲ +209.4% |
| 2012 | 0.12x | CN¥56.20 Million | CN¥459.72 Million | ▲ +337.8% |
| 2011 | 0.03x | CN¥12.09 Million | CN¥432.93 Million | ▲ +504.5% |
| 2010 | 0.00x | CN¥1.90 Million | CN¥411.28 Million | ▼ -88.5% |
| 2009 | 0.04x | CN¥17.88 Million | CN¥443.70 Million | ▲ +3.4% |
| 2008 | 0.04x | CN¥21.46 Million | CN¥550.51 Million | ▲ +218.8% |
| 2007 | -0.03x | CN¥-18.30 Million | CN¥557.68 Million | ▼ -145.9% |
| 2006 | 0.07x | CN¥33.63 Million | CN¥470.56 Million | ▲ +61.4% |
| 2005 | 0.04x | CN¥18.92 Million | CN¥427.37 Million | ▼ -43.8% |
| 2004 | 0.08x | CN¥26.90 Million | CN¥341.74 Million | ▼ -45.0% |
| 2003 | 0.14x | CN¥47.20 Million | CN¥329.82 Million | ▲ +36.9% |
| 2002 | 0.10x | CN¥32.85 Million | CN¥314.23 Million | ▲ +36.4% |
| 2001 | 0.08x | CN¥15.47 Million | CN¥201.82 Million | ▼ -53.0% |
| 2000 | 0.16x | CN¥20.55 Million | CN¥126.01 Million | ▲ +239.2% |
| 1999 | 0.05x | CN¥2.25 Million | CN¥46.73 Million | — |